Candel Therapeutics Stock Today
| CADL Stock | USD 6.96 0.32 4.82% |
Performance7 of 100
| Odds Of DistressOver 73
|
Candel Therapeutics is selling for 6.96 as of the 31st of January 2025. This is a 4.82 percent increase since the beginning of the trading day. The stock's lowest day price was 6.75. Candel Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of December 2024 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of July 2021 | Category Healthcare | Classification Health Care |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company was incorporated in 2003 and is based in Needham, Massachusetts. Candel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 32.48 M outstanding shares of which 2.92 M shares are currently shorted by private and institutional investors with about 7.72 trading days to cover. More on Candel Therapeutics
Moving together with Candel Stock
Moving against Candel Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Candel Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | FOCIS MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCandel Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Candel Therapeutics' financial leverage. It provides some insight into what part of Candel Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Candel Therapeutics (CADL) is traded on NASDAQ Exchange in USA. It is located in 117 Kendrick Street, Needham, MA, United States, 02494 and employs 42 people. Candel Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 134.29 M. Candel Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 32.48 M outstanding shares of which 2.92 M shares are currently shorted by private and institutional investors with about 7.72 trading days to cover.
Candel Therapeutics currently holds about 86.78 M in cash with (34.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0.
Check Candel Therapeutics Probability Of Bankruptcy
Ownership AllocationCandel Therapeutics holds a total of 32.48 Million outstanding shares. Candel Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Candel Ownership Details
Candel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 64.4 K | |
| Hb Wealth Management, Llc | 2024-09-30 | 56.7 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 46.8 K | |
| Bank Of New York Mellon Corp | 2024-09-30 | 45 K | |
| Jane Street Group Llc | 2024-09-30 | 32.8 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 30.3 K | |
| Barclays Plc | 2024-09-30 | 28.7 K | |
| Simplex Trading, Llc | 2024-09-30 | 22.8 K | |
| Rhumbline Advisers | 2024-09-30 | 22.5 K | |
| Northpond Ventures, Llc | 2024-09-30 | 1.9 M | |
| Blackrock Inc | 2024-09-30 | 1.1 M |
Candel Therapeutics Historical Income Statement
Candel Stock Against Markets
Candel Therapeutics Corporate Management
| Francesca MD | Chief Officer | Profile | |
| LLM JD | Chief Officer | Profile | |
| Nathan Caffo | Chief Officer | Profile | |
| MS MD | Chief Officer | Profile | |
| FMEDSCI MD | CEO Pres | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.